EXPEDEON
DGAP-News: Expedeon AG / Key word(s): Agreement PRESS RELEASE Expedeon AG announces commercial-use licence of proprietary technology in diagnostic assay Expedeon's colloidal gold is an aqueous suspension of spherical metallic nanoparticles manufactured to a high standard, demonstrating efficient antibody binding, for maximum sensitivity. PaxGenBio will deploy Expedeon's gold nanoparticles in its MPCR-ULFA (multiplexed Polymerase Chain Reaction - universal lateral flow assays) technology. These assays will be used for the early, simultaneous detection of sexually transmitted diseases, including human papillomavirus, and tuberculosis. The terms of the agreement is three years, with an option to extend. Dr. Youngsuk Park, CEO of PaxGenBio, said: "We are very pleased to be working with Expedeon and its highly-skilled, experienced team. Following a thorough evaluation of colloidal gold from a number of manufacturers, we identified the Expedeon product as the most consistent and of highest quality." Dr. Heikki Lanckriet, CEO and CSO of Expedeon, commented: "Expedeon is committed to providing our customers with the highest level of service, quality and consistency. We are delighted that PaxGenBio has chosen to adopt our gold nanoparticles in the manufacturing of its diagnostic kits. Our commercially scalable, proprietary colloidal gold particle manufacturing and coating process provides particles of the highest quality and offers superior properties in terms of particle size and shape and their ability to conjugate antibodies or antigens."
Expedeon AG MC Services AG (Investor Relations and International Media Relations) About Expedeon AG: www.expedeon.com ### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of Expedeon AG may deviate greatly from the established conclusions or implied predictions contained in such statements. Expedeon does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ### Additional features: Document: http://n.eqs.com/c/fncls.ssp?u=CXXMBRTFYX Document title: PGB_Eng
11.09.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | Expedeon AG |
| Waldhofer Str. 102 | |
| 69123 Heidelberg | |
| Germany | |
| Phone: | +49 (0) 6221 3540 125 |
| Fax: | +49 (0) 6221 3540 127 |
| E-mail: | investors@expedeon.com |
| Internet: | www.expedeon.com |
| ISIN: | DE000A1RFM03 |
| WKN: | A1RFM0 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| End of News | DGAP News Service |
722199 11.09.2018
